

Date: June 21, 2007

Subject: DRC Recommendations to DCC and DHS

To: DHS, DCC, Dean's Office

From: Henry F. Simmons, Jr., MD, Ph.D.
Chairman DRC

At its 06/21/07 meeting, the Drug Review Committee considered the potential toxicity and therapeutic roles of seven triptans in the management of adult patients with headaches.

The medications discussed included the following:

Almotriptan [Axert]
Eletriptan [Relpax]
Frovatriptan [Frova]
Naratriptan [Amerge]
Rizatriptan [Maxalt]
Sumatriptan [Imitrex]
Zolmitriptan [Zomig]

Based upon the bulk of the best available evidence pertaining to the aforementioned drugs the Committee concluded the following:

There is insufficient evidence to exclude completely any of the agents from therapeutic consideration on the basis of toxicity or an increased frequency of adverse effects.

At this time it cannot be concluded that one agent is generally superior to all of the others.

At least one nasal or one injectable dosage form should be available.

At least one orally disintegrating tablet should be available.

At least two oral formulations should be available.

There is insufficient evidence to conclude in general that any of the seven captioned drugs is either more efficacious or associated with more adverse effects than another based upon demographics, comorbidities or adverse drug interactions.